Revolutionary TB vaccine Trials : A century Long Wait for Innovation
Revolutionary TB vaccine Trials : A century Long Wait for Innovation
.png)
Tuberculosis (TB) remains one of the deadliest infectious diseases
globally, claiming nearly 1.5 million lives each year, mainly in low- and
middle-income countries. Despite significant advances in treatment and
diagnostics, the quest for an effective vaccine has persisted for over a
century.
The Current State of TB
Epidemiology and Impact
- Global Statistics: In 2021, an estimated 10.6
million people fell ill with TB. The highest incidence rates are found in
countries like India, China, Indonesia, the Philippines, and Pakistan.
- Drug-Resistant TB: The rise of drug-resistant strains, particularly multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), complicates treatment. In 2021, around 450,000 new cases of MDR-TB were reported, emphasizing the urgent need for more effective prevention strategies.
BCG Vaccine: A Historical Perspective
New Vaccine Trials: A Beacon of Hope
Why New Vaccines Matter
- Rising Drug Resistance: The emergence of multi-drug-resistant TB (MDR-TB) highlights the urgent need for a vaccine that can better prevent infection.
- Global Health Impact: A new vaccine could significantly reduce the incidence of TB, saving millions of lives and alleviating the burden on healthcare systems.
- Economic Benefits: Reducing TB incidence could lower healthcare costs and improve workforce productivity in affected regions.
New Vaccine Trials
A Phase 3 trial is currently in progress for what could become the first vaccine aimed at preventing pulmonary TB in adolescents and adults-the most prevalent form of the disease-and the first new TB vaccine in over a century.This trial, taking place in six provinces of South Africa, is testing the candidate M72/AS01E, designed to halt the progression to active pulmonary TB in adults infected with the bacteria that causes the disease.
Results from a Phase 2b clinical trial in Kenya, South
Africa, and Zambia indicated that two doses of M72/AS01E successfully reduced
the incidence of active TB by about 50%. This was a significant breakthrough in
TB vaccine research over the past few decades. If this efficacy is maintained
over 25 years, it could prevent 8.5 million deaths, avoid 76 million new TB
cases, and save affected households approximately $41.5 billion, according to
WHO estimates.
Kate O’Brien, WHO's director of the department of
immunization, vaccines, and biologicals, stated that the Strategic Advisory
Group of Experts on Immunization will closely monitor the trial's progress.
Since the BCG vaccine was introduced a century ago, it remains the only licensed TB vaccine, but its efficacy is limited, preventing only about 20% of infections in children and offering only partial protection against disease progression. TB claims over 1.3 million lives each year, with South Africa alone witnessing 280,000 new cases annually.
As the world watches the progress of new TB vaccine trials, the potential for a breakthrough could mark a transformative moment in public health. If successful, this new vaccine could not only save lives but also pave the way for a future where TB is no longer a global health threat. The next few years will be critical in determining whether we can finally turn the tide against this age-old disease.
.png)
.png)
.png)
.png)
.png)